Jeremiah de Leon1, Michael G Jameson2,3,4, David Rivest-Henault5, Sarah Keats2, Robba Rai2, Sankar Arumugam2, Lee Wilton6, Diana Ngo2, Gary Liney2,3,4, Daniel Moses4, Jason Dowling5, Jarad Martin6,7, Mark Sidhom2,4. 1. 1 Illawara Cancer Care Centre , Wollongong , Australia. 2. 2 Liverpool Cancer Therapy Centre , Liverpool , Australia. 3. 3 Ingham Institute for Applied Medical Research , Liverpool , Australia. 4. 4 Faculty of Medicine, University of New South Wales , Australia. 5. 5 Australian e-Health Research Centre, CSIRO , Herston , Australia. 6. 6 Calvary Mater Newcastle , Newcastle , Australia. 7. 7 Schoolof Medicine and Public Health, University of Newcastle , Newcastle , Australia.
Abstract
OBJECTIVE: PROMETHEUS (ACTRN12615000223538) is a multicentre clinical trial investigating the feasibility of 19 Gy in 2 fractions of stereotactic body radiotherapy (SBRT) as a boost technique for prostate cancer. The objective of this substudy was to evaluate intrafraction motion using cine MRI and assess the dosimetric impact of using a rectal displacement device (RDD). METHODS: The initial 10 patients recruited underwent planning CT and MRI, with and without a RDD. Cine MRI images were captured using an interleaved T2 HASTE sequence in sagittal and axial planes with a temporal resolution of 5.2 s acquired over 4.3 min. Points of interest (POIs) were defined and a validated tracking algorithm measured displacement of these points over the 4.3 min in the anteroposterior, superior-inferior and left-right directions. Plans were generated with and without a RDD to examine the impact on dosimetry. RESULTS: There was an overall trend for increasing displacement in all directions as time progressed when no RDD was in situ . points of interest remained comparatively stable with the RDD. In the sagittal plane, the RDD resulted in statistically significant improvement in the range of anteroposterior displacement for the rectal wall, anterior prostate, prostate apex and base. Dosimetrically, the use of a RDD significantly reduced rectal V16, V14 and Dmax, as well as the percentage of posterior rectal wall receiving 8.5 Gy. CONCLUSION: The RDD used in stereotactic prostate radiotherapy leads to reduced intrafraction motion of the prostate and rectum, with increasing improvement with time. It also results in significant improvement in rectal wall dosimetry. ADVANCES IN KNOWLEDGE: It was found that the rectal displacement device improved prostate stabilization significantly, improved rectum stabilization and dosimetry significantly. The rectal displacement device did not improve target volume dosimetry.
OBJECTIVE: PROMETHEUS (ACTRN12615000223538) is a multicentre clinical trial investigating the feasibility of 19 Gy in 2 fractions of stereotactic body radiotherapy (SBRT) as a boost technique for prostate cancer. The objective of this substudy was to evaluate intrafraction motion using cine MRI and assess the dosimetric impact of using a rectal displacement device (RDD). METHODS: The initial 10 patients recruited underwent planning CT and MRI, with and without a RDD. Cine MRI images were captured using an interleaved T2 HASTE sequence in sagittal and axial planes with a temporal resolution of 5.2 s acquired over 4.3 min. Points of interest (POIs) were defined and a validated tracking algorithm measured displacement of these points over the 4.3 min in the anteroposterior, superior-inferior and left-right directions. Plans were generated with and without a RDD to examine the impact on dosimetry. RESULTS: There was an overall trend for increasing displacement in all directions as time progressed when no RDD was in situ . points of interest remained comparatively stable with the RDD. In the sagittal plane, the RDD resulted in statistically significant improvement in the range of anteroposterior displacement for the rectal wall, anterior prostate, prostate apex and base. Dosimetrically, the use of a RDD significantly reduced rectal V16, V14 and Dmax, as well as the percentage of posterior rectal wall receiving 8.5 Gy. CONCLUSION: The RDD used in stereotactic prostate radiotherapy leads to reduced intrafraction motion of the prostate and rectum, with increasing improvement with time. It also results in significant improvement in rectal wall dosimetry. ADVANCES IN KNOWLEDGE: It was found that the rectal displacement device improved prostate stabilization significantly, improved rectum stabilization and dosimetry significantly. The rectal displacement device did not improve target volume dosimetry.
Authors: A R Padhani; V S Khoo; J Suckling; J E Husband; M O Leach; D P Dearnaley Journal: Int J Radiat Oncol Biol Phys Date: 1999-06-01 Impact factor: 7.038
Authors: Michel J Ghilezan; David A Jaffray; Jeffrey H Siewerdsen; Marcel Van Herk; Anil Shetty; Michael B Sharpe; Syed Zafar Jafri; Frank A Vicini; Richard C Matter; Donald S Brabbins; Alvaro A Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-01 Impact factor: 7.038
Authors: Katja M Langen; Twyla R Willoughby; Sanford L Meeks; Anand Santhanam; Alexis Cunningham; Lisa Levine; Patrick A Kupelian Journal: Int J Radiat Oncol Biol Phys Date: 2008-02-14 Impact factor: 7.038
Authors: Christopher R King; Debra Freeman; Irving Kaplan; Donald Fuller; Giampaolo Bolzicco; Sean Collins; Robert Meier; Jason Wang; Patrick Kupelian; Michael Steinberg; Alan Katz Journal: Radiother Oncol Date: 2013-09-20 Impact factor: 6.280
Authors: Christoph Oehler; Nina Roehner; Marcin Sumila; Jürgen Curschmann; Fabrizio Storelli; Daniel Rudolf Zwahlen; Uwe Schneider Journal: Curr Oncol Date: 2022-08-31 Impact factor: 3.109
Authors: Alexandre Taillez; Andre-Michel Bimbai; Thomas Lacornerie; Marie-Cecile Le Deley; Eric F Lartigau; David Pasquier Journal: Front Oncol Date: 2021-07-14 Impact factor: 6.244